Blair William & CO Immunity Bio, Inc. Transaction History

Blair William & CO

$32.2 Billion
Q1 2025

A detailed history of Blair William & CO transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Blair William & CO holds 233,500 shares of IBRX stock, worth $677,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares

233,500

Previous 233,500 -0.0%

Holding current value

$677,150

Previous $597,000 17.59%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$2.56 - $6.17 $68,352 - $164,739	26,700 Added 12.91%	233,500 $597,000
Q2 2024 Aug 12, 2024	SELL	$4.82 - $9.15 $514,496 - $976,689	-106,742 Reduced 34.04%	206,800 $1.31 Million
Q1 2024 May 09, 2024	BUY	$3.23 - $6.17 $521,741 - $996,640	161,530 Added 106.26%	313,542 $1.68 Million
Q4 2023 Feb 12, 2024	SELL	$1.25 - $5.21 $13,062 - $54,444	-10,450 Reduced 6.43%	152,012 $763,000
Q3 2023 Nov 09, 2023	BUY	$1.29 - $3.1 $139,875 - $336,136	108,431 Added 200.68%	162,462 $274,000
Q2 2023 Aug 11, 2023	BUY	$1.53 - $6.41 $1,530 - $6,410	1,000 Added 1.89%	54,031 $150,000
Q4 2022 Feb 10, 2023	SELL	$4.35 - $6.77 $2,175 - $3,385	-500 Reduced 0.93%	53,031 $268,000
Q2 2022 Aug 10, 2022	BUY	$2.68 - $6.14 $55,023 - $126,060	20,531 Added 62.22%	53,531 $199,000
Q3 2021 Nov 12, 2021	BUY	$9.17 - $14.24 $73,360 - $113,920	8,000 Added 32.0%	33,000 $321,000
Q2 2021 Aug 12, 2021	BUY	$13.41 - $22.4 $107,280 - $179,200	8,000 Added 47.06%	25,000 $357,000
Q1 2021 May 13, 2021	BUY	$12.83 - $42.25 $218,110 - $718,250	17,000 New	17,000 $404,000

Others Institutions Holding IBRX

# of Institutions

239

Shares Held

79.9M

Call Options Held

1.08M

Put Options Held

2.73M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.16B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account